综述

共感染视角下人类免疫缺陷病毒与巨细胞病毒致神经系统损伤的机制及研究进展

  • 王耀 ,
  • 魏兰兰 ,
  • 初明 ,
  • 王福祥
展开
  • 1.深圳市第三人民医院 a. 感染重症医学科;b. 肝病研究所 国家传染病临床研究中心;c. 神经外科,广东 深圳, 518112
    2.佳木斯大学基础医学院,黑龙江 佳木斯,154007
*:王耀与魏兰兰为并列第一作者
初 明 E-mail:chuming120@163.com; 王福祥 E-mail:13927486077@163.com

收稿日期: 2026-01-16

  修回日期: 2026-03-03

  录用日期: 2026-03-05

  网络出版日期: 2026-04-08

基金资助

国家自然科学基金面上项目(82272318);深圳市医学研究专项资金临床医学专项(C2401021);深圳市第三人民医院;经深圳市重大新发突发传染病临床医学研究中心项目(20230731105307002);深圳市“三名工程”医学团队项目(SZSM202311033)

版权

《内科理论与实践》编辑部, 2025, 版权所有,未经授权,不得转载、摘编本刊文章,不得使用本刊的版式设计。

Mechanisms and research progress of neurological damage caused by HIV and CMV from the perspective of co-infection

  • WANG Yao ,
  • WEI Lanlan ,
  • CHU Ming ,
  • WANG Fuxiang
Expand
  • 1. a. Intensive Care Unit for Infectious Diseases; b. Institute of Liver Diseases, National Clinical Research Center for Infectious Diseases; c. Department of Neurosurgery, Shenzhen Third People's Hospital, Shenzhen 518112, China
    2. College of Basic Medical Sciences, Jiamusi University, Jiamusi 154007, China

Received date: 2026-01-16

  Revised date: 2026-03-03

  Accepted date: 2026-03-05

  Online published: 2026-04-08

Copyright

, 2025, Copyright reserved © 2025.

摘要

随着抗逆转录病毒治疗(antiretroviral therapy,ART)的普及,人类免疫缺陷病毒(human immunodeficiency virus,HIV)感染者的寿命显著延长,但HIV相关神经认知障碍(HIV-associated neurocognitive disorder,HAND)的患病率并未同步下降。巨细胞病毒(cytomegalovirus, CMV)作为一种潜伏性机会性病原体,在HIV感染者中普遍存在,其与HIV的共感染可能通过协同作用加剧神经系统损伤,已成为影响患者长期生活质量和预后的关键因素。本文旨在系统阐述HIV与CMV共感染导致神经系统损伤的病毒学与免疫学基础、分子细胞机制、临床表型、诊断策略及治疗管理,并梳理最新研究进展与未来方向,为临床实践和科学研究提供整合性视角。

本文引用格式

王耀 , 魏兰兰 , 初明 , 王福祥 . 共感染视角下人类免疫缺陷病毒与巨细胞病毒致神经系统损伤的机制及研究进展[J]. 内科理论与实践, 2026 , 21(01) : 62 -67 . DOI: 10.16138/j.1673-6087.2026.01.09

Abstract

With the widespread use of antiretroviral therapy (ART), the lifespan of individuals infected with human immunodeficiency virus (HIV) has been significantly prolonged; however, the prevalence of HIV-associated neurocognitive disorder (HAND) has not decreased correspondingly. Cytomegalovirus (CMV), as a latent opportunistic pathogen, is prevalent among HIV-infected individuals. Co-infection of CMV and HIV may exacerbate neurological damage through synergistic effects and has become a key factor affecting the long-term quality of life and prognosis of patients. This article aims to systematically elucidate the virological and immunological basis, molecular and cellular mechanisms, clinical phenotypes, diagnostic strategies, and therapeutic management of neurological damage caused by HIV and CMV co-infection, and to summarize the latest research progress and future directions, providing an integrated perspective for clinical practice and scientific research.

参考文献

[1] UNAIDS. Global HIV & AIDS statistics — fact sheet [EB/OL]. (2025)[2025-12-07]. https://www.unaids.org/en/resources/fact-sheet.
[2] Mohammadzadeh N, Chomont N, Estaquier J, et al. Is the central nervous system reservoir a hurdle for an HIV cure?[J]. Viruses, 2023, 15(12):2385.
[3] Flanders DW, Lally C, Dilley A, et al. Estimated cytomegalovirus seroprevalence in the general population of the United States and Canada[J]. J Med Virol, 2024, 96(3):e29525.
[4] Gianella S, Massanella M, Wertheim JO, et al. The sordid affair between human herpesvirus and HIV[J]. J Infect Dis, 2015, 212(6):845-852.
[5] Zhao M, Zhuo C, Li Q, et al. Cytomegalovirus (CMV) infection in HIV/AIDS patients and diagnostic values of CMV-DNA detection across different sample types[J]. Ann Palliat Med, 2020, 9(5):2710-2715.
[6] Tejada-Pineda MF, Hoyo-Ulloa I, Ortega-Porcayo LA, et al. Cytomegalovirus (CMV)-driven transformation: an uncommon cause of a central nervous system pseudotumor[J]. Cureus, 2023, 15(8):e44188.
[7] Tanyel E, Tanyel C, Ersar? SS, et al. Management of CMV encephalitis with persistent CSF CMV DNA in a patient with HIV: a case report of successful treatment with ganciclovir-foscarnet combination therapy[J]. BMC Infect Dis, 2025, 25(1):1355.
[8] Oyedele BS, Ade TI, Famakinwa AA. Prevalence of cytomegalovirus among HIV patients attending Sobi Specialist Hospital, Ilorin, Nigeria[J/OL]. Int J Biomed Health Sci, (2024)[2025-12-18]. https://ijbhs.org/wp-content/uploads/2024/08/Oyedele-et-al_2024_Prevalence-of-cytomegalovirus-among-HIV-patients-attending-Sobi.pdf.
[9] Jabbari MR, Soleimanjahi H, Shatizadeh Malekshahi S, et al. Frequency of cytomegalovirus viral load in Iranian human immunodeficiency virus-1-infected patients with CD4+ counts <100 cells/mm3[J]. Intervirology, 2021, 64(3):135-139.
[10] Letendre S, Bharti A, Perez-Valero I, et al. Higher anti-cytomegalovirus immunoglobulin G concentrations are associated with worse neurocognitive performance during suppressive antiretroviral therapy[J]. Clin Infect Dis, 2018, 67(5):770-777.
[11] Li N, Zheng HY, Li W, et al. Limited restoration of T cell subset distribution and immune function in older people living with HIV-1 receiving HAART[J]. Immun Ageing, 2025, 22(1):3.
[12] Joy J, Gervassi A, Chen L, et al. Antigen specificities and proviral integration sites differ in HIV-infected cells by timing of antiretroviral treatment initiation[J]. J Clin Invest, 2024, 134(14):e159569.
[13] Vupmandla, N, Shivaswamy RP, Subhash Chandra BJ, et al. Challenges of managing HIV cytomegalovirus co-infection in the presence of pancytopenia[J/OL]. Indian Journal of Case Reports, (2023)[2025-12-20]. https://doi.org/10.32677/ijcr.v9i6.4026.
[14] Munks MW, Rott K, Nesterenko PA, et al. Latent CMV infection of lymphatic endothelial cells is sufficient to drive CD8 T cell memory inflation[J]. PLoS Pathog, 2023, 19(1):e1010351.
[15] Huang SN, Pan YT, Zhou YP, et al. Human cytomegalovirus IE1 impairs neuronal migration by downregulating connexin 43[J]. J Virol, 2023, 97(5):e0031323.
[16] Erice A, Tierney C, Hirsch M, et al. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360)[J]. Clin Infect Dis, 2003, 37(4):567-578.
[17] Calado M, Ferreira R, Pires D, et al. Unravelling the triad of neuroinvasion, neurodissemination, and neuroinflammation of human immunodeficiency virus type 1 in the central nervous system[J]. Rev Med Virol, 2024, 34(3):e2534.
[18] Mielcarska MB, Rouse BT. Viruses and the brain-a relationship prone to trouble[J]. Viruses, 2025, 17(2):203.
[19] Zhou Z, Wang W, Li H, et al. Decoding HIV-associated neurocognitive disorders: a new perspective from multimodal connectomics[J]. Front Neurol, 2025, 16:1467175.
[20] Zhao N, Chung TD, Guo Z, et al. The influence of physiological and pathological perturbations on blood-brain barrier function[J]. Front Neurosci, 2023, 17:1289894.
[21] Wahl A, Al-Harthi L. HIV infection of non-classical cells in the brain[J]. Retrovirology, 2023, 20(1):1.
[22] Chen W, Berkhout B, Pasternak AO. Phenotyping viral reservoirs to reveal HIV-1 hiding places[J]. Curr HIV/AIDS Rep, 2025, 22(1):15.
[23] da Silva AL, Guedes BLM, Santos SN, et al. Beyond pathogens: the intriguing genetic legacy of endogenous retroviruses in host physiology[J]. Front Cell Infect Microbiol, 2024, 14:1379962.
[24] Kelnhofer-Millevolte LE, Smith JR, Nguyen DH, et al. Human cytomegalovirus induces neuronal gene expression through IE1 for viral maturation[J]. Nat Commun, 2025, 16(1):7316.
[25] Nickoloff-Bybel EA, Festa L, Meucci O, et al. Co-receptor signaling in the pathogenesis of neuroHIV[J]. Retrovirology, 2021, 18(1):24.
[26] Zou JH, Zhou BL, Chen JY, et al. HIV-1 gp120 impairs blood-brain barrier via inducing brain endothelial pyroptosis[J/OL]. Blood, (2024)[2025-12-20]. https://doi.org/10.1182/blood-2024-198575.
[27] Singh S, Deshetty UM, Ray S, et al. Non-coding RNAs in HIV infection, neuroHIV, and related comorbidities[J]. Cells, 2024, 13(11):898.
[28] Zhang H, Yuan S, Ding S, et al. Molecular interplay of ASNS and the PI3K-AKT-mTOR pathway in CMV and HIV co-infections: therapeutic implications[J]. PLoS One, 2026, 21(2):e0342050.
[29] Tang QQ, Wu H, Tang MG. Recent advances in HIV-associated neurocognitive disorders[J/OL]. Journal of Biosciences and Medicines, (2023)[2025-12-21]. https://doi.org/10.4236/jbm.2023.119013.
[30] Wei J, Hou J, Su B, et al. The prevalence of Frascati-criteria-based HIV-associated neurocognitive disorder (HAND) in HIV-infected adults: a systematic review and meta-analysis[J]. Front Neurol, 2020, 11:581346.
[31] Starnes V, Soewarna V, Hollingshead C, et al. CMV transverse myelitis in unmanaged HIV infection[J/OL]. Translation, (2023)[2025-12-22]. https://openjournals.utoledo.edu/index.php/translation/article/view/760.
[32] Behar R, Wiley C, McCutchan JA. Cytomegalovirus polyradiculoneuropathy in acquired immune deficiency syndrome[J]. Neurology, 1987, 37(4):557-561.
[33] Halichidis S, Aschie M, Cozaru GC, et al. CMV and HIV coinfection in women from a region in Eastern Europe[J]. J Pers Med, 2023, 13(11):1539.
[34] Benadda S, Achour N, Ziane H, et al. CMV retinitis in HIV-infected patients: plasma viral load utility in diagnosis[J]. Diagn Microbiol Infect Dis, 2025, 113(2):116926.
[35] Davis K, Grant KG, Sousou JM, et al. Ethical and clinical considerations in the workup of HIV-associated neurocognitive decline[J]. Cureus, 2025, 17(11):e97348.
[36] Luo H, Chen J, Liu J, et al. Bridging brain and blood: a prospective view on neuroimaging-exosome correlations in HIV-associated neurocognitive disorders[J]. Front Neurol, 2025, 15:1479272.
[37] McCutchan JA. Cytomegalovirus infections of the nervous system in patients with AIDS[J]. Clin Infect Dis, 1995, 20(4):747-754.
[38] 中华医学会感染病学分会艾滋病丙型肝炎学组. 艾滋病合并巨细胞病毒病诊疗专家共识(2024年版)[J]. 中华传染病杂志, 2024, 42(3):129-140.
  AIDS and Hepatitis C Professional Group of Society of Infectious Diseases of Chinese Medical Association. Expert consensus on diagnosis and treatment of cytomegalovirus disease in acquired immunodeficiency syndrome patients in China (2024 edition)[J]. Chin J Infect Dis, 2024, 42(3):129-140.
[39] Allaw F, Haddad SF, Zakhour J, et al. Management of cytomegalovirus infection in allogeneic hematopoietic stem cell transplants[J]. Int J Antimicrob Agents, 2023, 62(2):106860.
[40] Wang W, Yang J, Liu X, et al. Successfully salvaging a HIV-positive patient with mixed CIDP and meningoencephalitis: a case report[J]. Front Med (Lausanne), 2025, 12:1537160.
[41] Porter LB, Kozakewich E, Clouser R, et al. Occam’s razor need not apply: advanced HIV infection presenting with five simultaneous opportunistic infections and central nervous system lymphoma[J]. IDCases, 2018, 13:e00437.
[42] Hong S, Banks WA. Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications[J]. Brain Behav Immun, 2015, 45:1-12.
[43] Freeman ML, Mudd JC, Shive CL, et al. CD8 T-cell expansion and inflammation linked to CMV coinfection in ART-treated HIV infection[J]. Clin Infect Dis, 2016, 62(3):392-396.
[44] Rinaldo CR. Cytomegalovirus: 40 years and still the major viral cofactor in HIV infection[J]. AIDS, 2022, 36(9):1311-1313.
[45] He Q, Liu J, Liang J, et al. Towards improvements for penetrating the blood-brain barrier-recent progress from a material and pharmaceutical perspective[J]. Cells, 2018, 7(4):24
[46] Hameed H, Faheem S, Younas K, et al. A comprehensive review on lipid-based nanoparticles via nose to brain targeting as a novel approach[J]. J Microencapsul, 2024, 41(8):681-714.
[47] Palma P, Costa A, Duro R, et al. Mononeuritis multiplex: an uncommon neurological manifestation of cytomegalovirus reactivation in an HIV-infected patient[J]. BMC Infect Dis, 2018, 18(1):554.
文章导航

/